invest summari beat ahead import pipeline/regulatori
advanc improv earn visibl reiter ow rate
month price target share think sale growth higher end
mid singl digit guidanc mid oper leverag pipelin
advanc return capit sharehold underappreci
therefor multipl expans drive share higher opinion
 takeaway support posit thesi announc transact
combin upjohn unit creat new global pharma
compani expect deliv revenu growth
higher end mid singl digit pro forma remainco growth
organ revenu reflect oper growth driven
oper growth biopharma biopharma sale total
driven ibranc global eliqui global xeljanz
global updat financi guidanc primarili reflect
anticip format consum healthcar jv gsk
nc anticip near-term complet arri cover
kumar deal exclud chang guidanc relat pend busi
develop activ guidanc unchang
remain share repurchas author upjohn
given oper growth outlook remaind
year revenu upjohn china full year expect grow low
mid singl digit oper base assess total
tanezumab data initi discuss fda ow
decid pursu regulatori submiss tanezumab mg sc
oa patient expect file fda
follow potenti regulatori file eu japan
report adjust dilut ep factset
higher estim lower ep guidanc
factset consensu adjust
financi model report decreas ep
 valuat use blend dcf multipl ev/ebitda analysi get
price target
disclosur section may found page
use blend dcf multipl ev/ebitda analysi get price
target
sever potenti risk invest thesi price target
product repres signific portion sale could face gener
competit current portfolio product may face competit cannib
pipelin introduct new competit could diminish price
power exist drug record direct product and/or allianc revenu
billion nine biopharmaceut product prevnar lyrica
ibranc eliqui enbrel lipitor xeljanz viagra sutent account total
revenu product pfizer major product subject
problem loss patent protect applic chang prescript growth rate
affect doctor patient confid pressur exist competit product chang
label access pressur new more-effect treatment introduc
advers impact revenu could signific
pipelin delay failur and/or higher-than-forecast competit gener
may continu face access challeng biosimilar product market
biosimilar product may receiv access pariti innov product remain
disadvantag posit exampl inflectra/remsima experienc access challeng
risk relat strateg acquisit success acquisit hospira
anacor mediv astrazeneca small molecul anti-infect busi depend
larg part compani abil realiz anticip benefit combin
busi exist segment exampl may fail achiev anticip
cost save acquisit hospira cost save within expect time
frame accret impact anticip acquisit hospira anacor
mediv may realiz may delay also may fail gener revenu
growth acquir busi expect time enter transact
bull bear base case analysi
also use blend dcf multipl ev/ebitda analysi arriv bull
bear case scenario base analysi estim likelihood stock worth
next month
exhibit bull bear base case scenario analysi
cantor fitzgerald research compani reportsbul casesal ibranc eliqui xeljanzand key drug exceed expectationspipelin advanc exceed expectationsstrateg accret scenario casesal ibranc eliqui xeljanzand key drug in-lin expectationspipelin advanc line expectationsno scenario casesal ibranc eliqui xeljanzand key drug expectationspipelin advanc expectationsno scenario exhibit varianc analysi
amount chang yoyamount chang yoyvariancecommentstot oper growth biopharma ibranc xtandi inlyta xeljanz eliqui driven mainli favor impact foreign exchang gross favor impact foreign oper non oper pre-tax tax net dilut share adjust dilut cantor fitzgerald research compani reportsactualcantor exhibit catalyst event calendar
datedriverupcom avelumabiniti phase trial head neck squamou cell talazoparib comboiniti phase trial enzalutamid comboiniti phase trial biosimilar trazimera eu japan data vaso-occlus crisi hospit subject sickl cell biopharmacomplet biosimilarjapan adalimumab biosimilar bsufa adalimumab biosimilar japan multival pneumococc conjug vaccin phase infant proof-of-concept mektovi cetuximabsubmit beacon data regulatori review coagul factor ix gene therapi initi pivot phase hemophilia palbociclib ibranc present preliminari phase data healthcar businessclos transact gsk fall abrocitinib phase jade moder sever ad top-line readoutdecemb vaccinephas data respiratori syncyti viru decemb multival pneumococc conjug vaccin estimate primari complet date phase trial adult year age older decemb multival pneumococc conjug vaccin estimate primari complet date phase trial year biosimilar rituximab safeti efficaci result phase data javelin lung data nsclc therapeuticsent phase partial agonist parkinson diseas loe impact expectedl data bladder regulatori submiss mg sc moderate-to-sever oa end inject businessexpect suppli constraint issu significantli improvedbi end xeljanz complet safeti evalu ra indic updat patent isavuconazol addit launchessourc cantor fitzgerald research compani report exhibit catalyst event calendar continu
datedriverupcom avelumab best support care phase javelin bladder data bladder mainten javelin gastric data gastric mainten mini-dystrophin gene therapi initi phase trial duchenn muscular dystrophi dmd januari multival pneumococc conjug vaccin estimate primari complet date pivot phase trialapril anti data atop upjohn mylclos month stay expiresnovemb patent palbociclib phase patina data breast abrocitinib phase jade compar moder sever ad top-line tfpi mab phase data hemophilia data crohn talazoparib avelumabphas javelin parp medley data local advanc metastat solid talazoparib phase data metastat data activ non-segment therapeut vaccin phase data vaccine-bas immunotherapi regimen prostat data moder sever ulcer prophylact vaccin phase clover data clostridium difficil data ankylos enzalutamid leuprolidephas embark data nonmetastat hspc palbociclib phase penelop data high-risk earli breast palbociclib phase palla data intermediate-risk earli breast end multival pneumococc conjug vaccin potenti file adult earli readout cancer pain studi asept process map facilitycomplet construct portag combo w/ soc chemoradi crt phase javelin head neck data head neck talazoparib avelumabphas javelin brca/atm data metastat solid tumor brca atm eu patent eu patent oral inhibitor phase pivot readout alopecia areata end co-promot talazoparib w/ novel hormon therapi nht phase data metastat castration-resist patent patent palbociclib us/major eu/japan patent palbociclib major eu patent adalimumab biosimilar licens period begin per agreement asept process map facilitybegin product portag patent patent eu/japan patent patent eu patent patent eu/japan patent eu patent enzalutamid us patent patent eu patent patent patent patent patent talazoparib us patent expir file extend actual ext grant could avelumab major eu/japan patent avelumab us patent lorlatinib us patent expirationsourc cantor fitzgerald research compani report exhibit cantor estim versu manag guidanc
exhibit incom statement analysi
exhibit margin analysi
exhibit quarterli sale analysi
exhibit annual sale analysi
exhibit analysi
exhibit balanc sheet analysi
pfizer inc engag discoveri develop manufactur healthcar product
analyst primarili respons research report whose name appear front cover certifi view express
research report accur reflect person view subject secur issuer featur report ii part
research analyst compens directli indirectli relat specif recommend view express
research analyst report
invest bank next month cantor fitzgerald and/or affili expect receiv intend seek compens invest bank
servic within next three month compani referenc within report
cantor fitzgerald and/or affili market maker inc
lead co-manag cantor fitzgerald and/or affili act lead co-manag public offer equiti and/or debt secur array
biopharma inc within last month
invest bank last month cantor fitzgerald and/or affili receiv compens invest bank servic last month
array biopharma inc
cantor fitzgerald and/or affili market maker array biopharma inc
cantor fitzgerald and/or affili market maker eli lilli compani
cantor fitzgerald and/or affili market maker inc
overweight/ow analyst expect stock total return stock price appreci plu dividend outperform rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month overweight rate equat buy rate
neutral analyst expect stock total return stock price appreci plu dividend perform line rel analyst broadli
defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month neutral rate equat hold rate
underweight/uw analyst expect stock total return stock price appreci plu dividend under-perform rel analyst
broadli defin sector next month purpos calcul percentag subject compani within buy hold sell categori
cantor fitzgerald provid invest bank servic within previou month underweight rate equat sell rate
covered/nc cantor fitzgerald provid invest opinion provid research coverag stock
rated/nr current carri rate stock rate estim review nr rate equat overweight
neutral underweight rate thu count calcul percentag subject compani within three categori
cantor fitzgerald provid invest bank servic within previou month
